The achievements of two IBPR interdisciplinary/cross-unit new drug development projects, “DBPR168: Neuroprotective Drug DBPR168 for Preventing Chemotherapy-Induced Peripheral Neuropathy” and “DBPR22998: Novel Broad-Spectrum Cancer Immunotherapy Targeting CD47-SIRPα “Do-not-eat- me” have been awarded the 20th National Innovation Award/School-Research Innovation Award in the Biopharmaceuticals and Precision Medicine category:
Project “DBPR168: Neuroprotective Drug DBPR168 for Preventing Chemotherapy-Induced Peripheral Neuropathy”: a cross-unit collaboration with National Cheng Kung University.
★IBPR Research teams: Kak-Shan Shia (夏克山), Jang-Yang Chang (張俊彥/本所合聘特聘研究員;臺北癌症中心)
★National Cheng Kung University team: Meng-Ru Shen (沈孟儒)
Project “DBPR22998: Novel Broad-Spectrum Cancer Immunotherapy Targeting CD47-SIRPα “Do-not-eat- me”: a cross-unit collaboration with Academia Sinica.
★IBPR Research teams: Jyh-Haur Chern (陳志豪), Teng-Kuang Yeh (葉燈光), Chiung-Tong Chen(陳炯東)
★Academia Sinica teams: Andrew H.-J. Wang(王惠鈞), Kai-Fa Hwang(黃開發)
